Skip to main content

USPTO to Re-examine ExonHit Patent

NEW YORK (GenomeWeb News) – Jivan Biologics said yesterday that the US Patent and Trademark Office will re-examine a patent held by Paris-based ExonHit Therapeutics covering methods for identifying differentially spliced gene products.
 
The patent, No. 6,881,571, is at the center of a patent infringement suit filed last year by ExonHit against Larkspur, Calif.-based Jivan.
 
Earlier this year, Jivan requested a re-examination of all the claims in the patent on the basis of prior art that it believes was not considered during the original patent examination.
 
“We expect the patent office to consider whether claims in the ‘571 patent should be amended or invalidated in their entirety,” Jivan CEO Subha Srinivasan said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.